Immunovant (IMVT) Non-Current Assets (2018 - 2026)

Immunovant (IMVT) has 9 years of Non-Current Assets data on file, last reported at $8.2 million in Q1 2026.

• Quarterly Non-Current Assets fell 4.26% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.7 million (up 41.75% YoY) and the FY2026 annual result came in at $8.2 million, down 4.26% from the prior year.
• Non-Current Assets eased to $8.2 million in Q1 2026, from $9.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $9.7 million in Q2 2025 to a low of $595000.0 in Q1 2024.
• A 5-year average of $4.5 million and a median of $2.4 million in 2022 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 63.21% — and 2025, when it soared 1433.6%.
• Tracing IMVT's Non-Current Assets over 5 years: stood at $1.8 million in 2022, then plunged by 63.21% to $670000.0 in 2023, then jumped by 1152.39% to $8.4 million in 2024, then rose by 12.66% to $9.5 million in 2025, then slipped by 13.31% to $8.2 million in 2026.
• The last three Non-Current Assets figures came in at $8.2 million (Q1 2026), $9.5 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.